Armata Pharmaceuticals, Inc. 8-K

Summary

AP-SA02 Phase 3 readiness update and CFO promotion. Armata submitted the complete Phase 3 protocol and responses to all FDA comments from its End-of-Phase 2 meeting, and completed four manufacturing engineering runs. The Phase 3 superiority study for adjunct treatment of complicated MSSA or MRSA bacteremia remains on track to start in H2 2026. David House was promoted to CFO on 7/20/2026; he has served as SVP, Finance and Principal Financial Officer since August 2024.

Key Figures

• DoD award: an additional $2.5M brings total funding received to date under the award to $28.7M. The new funds support Phase 3 preparation and readiness.

Investor Takeaways

• Clinical trial material production is the next planned manufacturing step; progress toward that step and Phase 3 initiation in H2 2026 will be key milestones.
• Armata is discussing potential additional DoD support, including for the Phase 3 study, and is pursuing other funding pathways.